A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants and patients with sickle cell disease (SCD).

Timeline

Start

2024-08-15

Primary completion

2028-05-01

Completion

2030-02-19

Drugs

Indications